Chikungunya vaccine enters Phase 3 clinical trial
by Press Release from Outbreak News Today on (#580YS)
Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot chikungunya vaccine candidate VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to [...]
The post Chikungunya vaccine enters Phase 3 clinical trial appeared first on Outbreak News Today.